Brief: Alphamab Oncology Says IND Approvals By China's Nmpa For A Phase Ia/Ib Clinical Trial- Of Kn052 In Treatment Of Advanced Solid
10/02/2022 15:33
Feb 10 (Reuters) - Alphamab Oncology 9966.HK :
* IND APPROVALS BY CHINA'S NMPA FOR A PHASE IA/IB CLINICAL
TRIAL-
OF KN052 IN TREATMENT OF ADVANCED SOLID
* IND APPROVAL BY CHINA'S NMPA FOR A PHASE II CLINICAL TRIAL
OF
KN046 IN COMBINATION WITH- AXITINIB IN TREATMENT OF ADVANCED
NSCLC
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)